GlassScriptPhysician profile
Tad Robert Kosanovich
NPI 1285785527
$9,917.78
in general payments reported to CMS, 2019-2025
23 companies · $508 in 2025
The $508 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,068 · 2020: $479 · 2021: $3,958 · 2022: $1,534 · 2023: $1,095 · 2024: $277 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,879.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $3,556.70 | 2019-2021 | |
| Coopervision INC. | $915.22 | 2019-2023 | Myday Contact Lens, Misight Contact Lens |
| Allergan, INC. | $748.39 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $561.59 | 2019-2025 | Acuvue |
| Sight Sciences, INC. | $551.12 | 2019-2022 | |
| Abbvie INC. | $510.33 | 2022-2023 | |
| Visionix USA, INC | $408.56 | 2022 | |
| Oyster Point Pharma, INC. | $381.83 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $324.67 | 2019 | |
| Bausch & Lomb Americas INC. | $247.46 | 2023-2025 | Miebo, Xiidra |
| Horizon Therapeutics Plc | $246.27 | 2022-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $243.29 | 2020-2024 | |
| Shire North American Group INC | $234.32 | 2019 | |
| Alcon Vision LLC | $197.25 | 2019-2025 | Voyager Dslt, Precision7 |
| Spark Therapeutics, INC. | $121.85 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $121.85 | 2025 | Xdemvy |
| Maculogix, INC. | $113.03 | 2019 | |
| Biotissue Holdings INC. | $106.71 | 2024 | |
| Rxsight INC | $96.52 | 2023 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Lombart Brothers, INC. | $68.70 | 2019 | |
| Dompe US, INC. | $58.59 | 2021 | |
| Lumibird Medical INC. | $53.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $49.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tad Kosanovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.